Physician profile
Phillip Wayne Jones
NPI 1871588806
$6,300.03
in general payments reported to CMS, 2019-2025
34 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $105 · 2021: $50.74 · 2022: $655 · 2023: $661 · 2024: $1,727 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,928 · Education: $171 · Consulting Fee: $51.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,928.43 |
| Education | $170.63 |
| Consulting Fee | $51.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,228.42 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,057.31 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Amgen INC. | $597.82 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $468.91 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $423.58 | 2021-2025 | Hyqvia, Takhzyro, Glassia |
| Genentech USA, INC. | $386.15 | 2023-2025 | Xolair |
| Csl Behring | $312.64 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $269.09 | 2024-2025 | Dupixent |
| Genzyme Corporation | $258.75 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $141.01 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $130.77 | 2025 | Nemluvio |
| Optinose US, INC. | $123.92 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $100.84 | 2025 | |
| Biocryst US Sales Co., LLC | $83.21 | 2023-2025 | Orladeyo |
| Octapharma USA, INC. | $79.55 | 2023-2024 | Cutaquig |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $54.15 | 2025 | Sajazir |
| Pfizer INC. | $53.68 | 2024-2025 | |
| Ionis Pharmaceuticals, INC. | $52.27 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $51.25 | 2024-2025 | |
| Mylan Specialty L.P. | $49.81 | 2022-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $48.99 | 2025 | |
| Sunovion Pharmaceuticals INC. | $48.37 | 2019 | |
| Paratek Pharmaceuticals, INC. | $35.00 | 2025 | Xhance |
| Abbvie INC. | $33.17 | 2022-2023 | |
| Verona Pharma, INC. | $33.16 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $31.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.43 | 2020-2022 | |
| Viatris Specialty LLC | $21.34 | 2025 | Yupelri |
| Pharming Healthcare, INC. | $19.16 | 2024 | Ruconest |
| Shire North American Group INC | $18.60 | 2019 | |
| Greer Laboratories, INC. | $16.57 | 2025 | Oralair |
| Insmed, INC. | $15.29 | 2020 | |
| Vifor Pharma, INC. | $14.27 | 2024 | Zemaira |
| Merck Sharp & Dohme LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.